Boundless Bio Statistics

Total Valuation

Boundless Bio has a market cap or net worth of $22.61 million. The enterprise value is -$67.07 million.

Market Cap	22.61M
Enterprise Value	-67.07M

Important Dates

The next estimated earnings date is Monday, August 11, 2025, after market close.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Boundless Bio has 22.38 million shares outstanding. The number of shares has increased by 1,701.54% in one year.

Current Share Class	22.38M
Shares Outstanding	22.38M
Shares Change (YoY)	+1,701.54%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	1.72%
Owned by Institutions (%)	49.75%
Float	14.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.16
P/TBV Ratio	0.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 22.15, with a Debt / Equity ratio of 0.36.

Current Ratio	22.15
Quick Ratio	21.81
Debt / Equity	0.36
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -54.06% and return on invested capital (ROIC) is -31.44%.

Return on Equity (ROE)	-54.06%
Return on Assets (ROA)	-29.89%
Return on Invested Capital (ROIC)	-31.44%
Return on Capital Employed (ROCE)	-39.87%
Revenue Per Employee	n/a
Profits Per Employee	-$1.03M
Employee Count	64
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -74.75% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-74.75%
50-Day Moving Average	1.35
200-Day Moving Average	2.23
Relative Strength Index (RSI)	34.09
Average Volume (20 Days)	366,091

Short Selling Information

The latest short interest is 584,677, so 2.61% of the outstanding shares have been sold short.

Short Interest	584,677
Short Previous Month	482,380
Short % of Shares Out	2.61%
Short % of Float	4.09%
Short Ratio (days to cover)	3.43

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-73.73M
Pretax Income	n/a
Net Income	-65.69M
EBITDA	-72.59M
EBIT	-73.73M
Earnings Per Share (EPS)	-$2.95

Full Income Statement

Balance Sheet

The company has $138.25 million in cash and $48.57 million in debt, giving a net cash position of $89.68 million or $4.01 per share.

Cash & Cash Equivalents	138.25M
Total Debt	48.57M
Net Cash	89.68M
Net Cash Per Share	$4.01
Equity (Book Value)	136.59M
Book Value Per Share	6.13
Working Capital	134.03M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$59.60 million and capital expenditures -$2.51 million, giving a free cash flow of -$62.11 million.

Operating Cash Flow	-59.60M
Capital Expenditures	-2.51M
Free Cash Flow	-62.11M
FCF Per Share	-$2.77

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Boundless Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,701.54%
Shareholder Yield	-1,701.54%
Earnings Yield	-290.57%
FCF Yield	-274.71%

Analyst Forecast

The average price target for Boundless Bio is $4.00, which is 296.04% higher than the current price. The consensus rating is "Buy".

Price Target	$4.00
Price Target Difference	296.04%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2